+149%

est. 2Y upside i

Series A

Rank

#151

Sector

Clinical Trial Technology

Est. Liquidity

~5Y

Data Quality

Data: Medium

Mural Health offers high potential upside (~149% expected 2-year return) driven by its innovative platform and market expansion, but severe preference overhang, stale valuation, and high dilution risk make it a high-risk equity bet.

Last updated: July 19, 2026

Bull (20%)+365%

Above-trend growth, strong market adoption, and potential IPO window support an 8x multiple on $10M revenue, yielding $80M exit; net of dilution, upside 365%.

Base (55%)+183%

Revenue reaches ~$10M with 30-40% growth, multiple improves to 5x in line with public comps, yielding $50M exit; net of 20% dilution, upside 183%.

Bear (25%)-100%

Even with modest revenue growth to $10M, a compressed 2x multiple yields $20M enterprise value, below $20.7M preference stack, implying -100% return for common equity.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

125%

Total funding of $20.7M exceeds the $16.5M entry valuation, creating a $4.2M preference overhang; in a low exit, common stock is fully wiped out.

Dilution Risk

moderate

With $5.5M ARR and estimated burn, a future round (20% dilution) is likely within 2-3 years.

Secondary Liquidity

none

No secondary market activity observed; shares are illiquid.

View all 4 open roles at Mural Health →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Mural Health's data — designed to show you've done your homework.

  • 1

    “How does Mural Health defend against incumbents like Oracle Clinical or Medidata?”

  • 2

    “What is the company's strategy for achieving profitability given the high preference stack?”

  • 3

    “How do you evaluate the residual risk of equity compensation given the current valuation staleness?”

Community

Valuation Sentiment

Our model estimates +149% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.